PrimeRFP SCOUT · Federal Contract Recompete Brief

HHSO100201600030C — EMERGENT AV7909 ANTHRAX VACCINE

EMERGENT AV7909 ANTHRAX VACCINE is a federal NONE award for Department of Health and Human Services (HHS) held by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.. Estimated value $1.4B ($663M obligated). Current period of performance ends Sep 29, 2026. Last award drew 1 bidder. Place of performance: GAITHERSBURG, MD. Related solicitation 16100SOL00015.

$1.4B
Estimated Value
$663M
Obligated
Sep 29, 2026
PoP End / Expires
1
Bidders (last award)

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See related expiring contracts →

Analysis

Public

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. holds $453.8M across 7 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Sep 29, 2026 PoP end — agencies typically plan 12–18 months ahead.

Contract facts

NONE
Contract numberHHSO100201600030C
AgencyDepartment of Health and Human Services (HHS)
IncumbentEMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.
UEICNPVCR8DK7M8
NAICS541711

No full NAICS 541711 intel page yet. Browse NAICS intelligence

PSCAN12
Place of performanceGAITHERSBURG, MD
Related solicitation16100SOL00015
PoP end (current)Sep 29, 2026
Obligated$663M

Recompete timing

Public
Expiring in 41 days

Current PoP ends Sep 29, 2026 (41 days remaining). Agencies typically plan 12–18 months ahead — at 1.3 months out, that window is already open. The buying decision is likely already in motion.

Watch this contract — one email →

Incumbent footprint

Public record

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.$453.8M obligated across 7 awards (firm-wide, all agencies).

Sole agency: Department of Health and Human Services (HHS)
Department of Health and Human Services (HHS)$459.1M · 100% of firm total
Open full company profile

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

Track this contract

Get an alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

See the recompete window for HHSO100201600030C
More in SCOUT
Track this contract →

Alert when the recompete window opens, the incumbent changes, or a protest lands. One email, no account.

Size up the competition →

See all live recompete landscapes — who else is expiring, and where the openings are.

Research the incumbent →

Open EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.

Frequently asked questions

What is contract HHSO100201600030C?

HHSO100201600030C (EMERGENT AV7909 ANTHRAX VACCINE) is a Department of Health and Human Services (HHS) award with an estimated value of $1.4B, currently held by EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.. Figures are USASpending-sourced public-record facts normalized by PrimeRFP SCOUT.

Who is the incumbent on HHSO100201600030C?

EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. is the incumbent with $453.8M across 7 related awards in SCOUT’s public footprint. The current period of performance ends Sep 29, 2026.

When does HHSO100201600030C come up for recompete?

SCOUT tracks a period-of-performance end of Sep 29, 2026. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Explore it live — $90 Pilot →

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HHSO100201600030C

SCOUT Signal

August 2026

$37.71BCivilian obligated

One VA health contract was 35% of civilian federal obligations in July.

Meanwhile VA's service-disabled veteran-owned contract actions fell 41.8%. The same agency, the same month, the large-vendor lane expanding while the small-business lane contracted. Figures are civilian-agency obligations through 2026-07-31; DoD FPDS for this window is labeled incomplete.

This issue is the whole civilian market. Your capture plan isn't.

Read the August 2026 issue →